Beam Therapeutics (NASDAQ:BEAM) Price Target Raised to $68.00 at Citigroup

Key Points

• Citigroup raised its price target on Beam Therapeutics to $68 (from $64) and maintained a "buy" rating, implying roughly a 186% upside, while MarketBeat data shows a consensus of "Moderate Buy" with an average target near $48.87.
• Beam reported compelling Phase 1/2 data for BEAM‑302, selected a 60 mg dose and plans a global pivotal cohort in H2 2026 pursuing accelerated FDA approval, but regulators and investors will watch safety signals (notably Grade 4 ALT and Grade 3 AST elevations) and execution/regulatory risks.
• The company posted a material earnings beat—$2.33 EPS vs. a ($1.13) estimate and $114.1M revenue versus $13.2M expected—yet remains unprofitable with negative margins and analysts still forecasting a ~-4.57 EPS for the fiscal year; the stock was trading around $23.74 with a ~$2.4B market cap.

Beam Therapeutics (NASDAQ:BEAM - Get Free Report) had its price target increased by research analysts at Citigroup from $64.00 to $68.00 in a research report issued on Thursday,Benzinga reports. The firm currently has a "buy" rating on the stock. Citigroup's price target suggests a potential upside of 186.45% from the company's current price.

Several other analysts also recently commented on BEAM. Royal Bank Of Canada raised their price objective on Beam Therapeutics from $22.00 to $26.00 and gave the stock a "sector perform" rating in a research note on Wednesday, February 25th. Weiss Ratings reissued a "sell (d-)" rating on shares of Beam Therapeutics in a research note on Wednesday, January 21st. Wall Street Zen upgraded Beam Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, February 28th. Tudor Pickering set a $41.00 price target on Beam Therapeutics in a research report on Wednesday, January 21st. Finally, Sanford C. Bernstein increased their target price on Beam Therapeutics from $37.00 to $41.00 and gave the stock an "outperform" rating in a research note on Tuesday, January 20th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $48.87.

Beam Therapeutics Stock Up 2.7%

NASDAQ BEAM traded up $0.62 during trading on Thursday, reaching $23.74. 917,553 shares of the stock traded hands, compared to its average volume of 1,952,354. Beam Therapeutics has a fifty-two week low of $13.52 and a fifty-two week high of $36.44. The firm has a market cap of $2.42 billion, a price-to-earnings ratio of -23.58 and a beta of 2.12. The stock's 50-day moving average price is $27.79 and its 200 day moving average price is $26.27.

Beam Therapeutics (NASDAQ:BEAM - Get Free Report) last posted its earnings results on Tuesday, February 24th. The company reported $2.33 earnings per share for the quarter, topping the consensus estimate of ($1.13) by $3.46. Beam Therapeutics had a negative net margin of 57.24% and a negative return on equity of 30.65%. The company had revenue of $114.11 million for the quarter, compared to analyst estimates of $13.22 million. During the same period last year, the business posted ($1.09) earnings per share. The business's revenue for the quarter was up 280.3% compared to the same quarter last year. Analysts anticipate that Beam Therapeutics will post -4.57 EPS for the current fiscal year.

Insider Transactions at Beam Therapeutics

In other Beam Therapeutics news, insider Christine Bellon sold 18,629 shares of the stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $34.61, for a total transaction of $644,749.69. Following the completion of the transaction, the insider owned 97,038 shares in the company, valued at approximately $3,358,485.18. This represents a 16.11% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 3.50% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of BEAM. Squarepoint Ops LLC boosted its position in Beam Therapeutics by 468.3% during the 2nd quarter. Squarepoint Ops LLC now owns 138,765 shares of the company's stock worth $2,360,000 after acquiring an additional 114,349 shares during the last quarter. Capital Fund Management S.A. bought a new stake in shares of Beam Therapeutics in the second quarter worth $654,000. Privium Fund Management B.V. bought a new stake in shares of Beam Therapeutics in the third quarter worth $1,480,000. Y Intercept Hong Kong Ltd acquired a new position in Beam Therapeutics during the third quarter worth $1,059,000. Finally, SG Americas Securities LLC boosted its holdings in Beam Therapeutics by 498.9% during the third quarter. SG Americas Securities LLC now owns 43,220 shares of the company's stock worth $1,049,000 after purchasing an additional 36,004 shares during the last quarter. 99.68% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Beam Therapeutics

Here are the key news stories impacting Beam Therapeutics this week:

• Positive Sentiment: Updated Phase 1/2 efficacy: a single 60 mg dose produced mean steady‑state total AAT of 16.1 µM (above the protective 11 µM threshold), durable functional increases, ~84% reduction in toxic Z‑AAT and ~94% corrected M‑AAT composition — data the company says support a one‑time corrective therapy. Beam Therapeutics Announces Compelling Updated Clinical Data...
• Positive Sentiment: Company advanced program plans: Beam selected 60 mg as the optimal biological dose and intends to start a global pivotal cohort in H2 2026 pursuing an FDA accelerated‑approval path with ~50 additional patients. Beam Discusses Topline Phase I/II Data for BEAM-302...
• Positive Sentiment: Broad positive press and market reaction: multiple outlets reported the results and noted share gains after the update, reinforcing near‑term investor enthusiasm. Beam Therapeutics stock jumps on positive trial data
• Neutral Sentiment: Company hosted an investor webcast to review the dataset and next steps; replay and slides are available for investors seeking detail on endpoints and safety. Beam Discusses Topline Phase I/II Data for BEAM-302...
• Neutral Sentiment: Third‑party recaps (BiopharmaDive, Benzinga, Quiver) summarize the same data, dose choice and timelines — useful for context but largely echo the company release. Beam posts positive data on base editing treatment for AATD
• Negative Sentiment: Safety signals to monitor: while no serious AEs were reported in single‑dose cohorts, the multi‑dose cohort included Grade 4 ALT and Grade 3 AST elevations in one patient and other transient LFT elevations — these will be focal points for regulators and investors as the program advances. Beam Therapeutics Announces Compelling Updated Clinical Data...
• Negative Sentiment: Execution and regulatory risk remain: the pivotal cohort is expected H2 2026 but timelines, durability beyond follow‑up windows, manufacturing and long‑term safety are open risks that could affect valuation and approval timing. Beam to advance gene-editing drug to pivotal development
• Neutral Sentiment: Short‑interest data in feeds appears inconsistent/erroneous (reported as zero) and is not meaningful for reading current sentiment. Beam Therapeutics shares climb after positive BEAM-302 trial update

Beam Therapeutics Company Profile

Beam Therapeutics, Inc NASDAQ: BEAM is a biotechnology company dedicated to developing precision genetic medicines through its pioneering base editing platform. Headquartered in Cambridge, Massachusetts, with additional research facilities in Philadelphia, the company focuses on engineering molecular editors capable of making precise single-nucleotide changes in DNA. By harnessing its proprietary base editing technology, Beam aims to correct or disrupt disease-causing genetic variants at their source, offering the potential for novel therapies in areas with significant unmet medical need.

Founded in 2017 as a spin-out from Harvard University and the Broad and Whitehead Institutes, Beam was co-founded by leading academic researcher David R.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.